The BioStabilization Systems (BoSS) program seeks to develop a bioprocessing system for scalable production of thermally stable cell-based therapies, eliminating the need for ultra-cold storage. The program aims to transform manufacturing and distribution of biologics, impacting healthcare areas like regenerative medicine and bio-surveillance. For performers, a Solution Summary is due by February 19, 2026, and for IV&V partners, by April 17, 2026. The IV&V Solution Pitch deadline has been extended to May 21, 2026, but the IV&V Solution Summary deadline remains unchanged. No budget amounts or specific performance location are specified.

This opportunity seeks to develop a bioprocessing system to stabilize live cell-based therapies without the need for ultra-cold storage, aiming to transform their manufacturing and distribution. The program also aims to accelerate advancements in related biotechnology areas like regenerative medicine and bio-surveillance. There are two distinct submission pathways: one for Performers with a solution summary due on February 19, 2026, and another for IV&V partners with a summary due on April 17, 2026. Several amendments have been issued to clarify proposal requirements, out-of-scope approaches, and reporting details. Interested parties must submit their solution summaries through a specified online portal.